Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts

Health Policy

Volumn 120, Issue 5, 2016, Pages 519-534

  Hu, Jia ^a   Mossialos, Elias ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

China; Pharmaceutical policy; Pricing; Reimbursement

Indexed keywords

CHINA; DRUG INDUSTRY; DRUG QUALITY; DRUG RESEARCH; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; INFORMATION PROCESSING; MEDICAL LITERATURE; PHARMACEUTICAL CARE; PROSPECTIVE PRICING; REIMBURSEMENT; REVIEW; STATISTICS; COST; COST CONTROL; DRUG COST; ECONOMICS; HEALTH CARE COST; HEALTH SERVICE; HUMAN; PHARMACOECONOMICS; PROCEDURES; STANDARDS; TRENDS;

CHINA; COST CONTROL; COSTS AND COST ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HEALTH EXPENDITURES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT;

EID: 84964322238     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2016.03.014     Document Type: Review

References (83)

1. OECD Health at a glance 2013 - OECD indicators 2013, Paris.
2. National Health Development Research Center China National Health Accounts Report 2013, Beijing.
3. IMS Health The global use of medicines: outlook through 2017 2013, London.
4. Yip W.C.M., Hsiao W.C., Chen W., Hu S., Ma J., Maynard A. Early appraisal of China's huge and complex health-care reforms. Lancet 2012, 379:833-842.
5. Ran L.M., Luo K.J., Wu Y.C., Yao L., Feng Y.M. An analysis of china's physician salary payment system. Journal of Huazhong University of Science and Technology. Medical Sciences 2013, 33:309-314. 10.1007/s11596-013-1116-9.
6. Chen Z. Launch of the health-care reform plan in China. The Lancet 2009, 373:1322-1324. 10.1016/S0140-6736(09)60753-4.
7. Central Committee of the Communist Party and State Council The standing conference of State Council of China adopted guidelines for furthering the reform of health-care system in principle 2009, http://news.xinhuanet.com/newscenter/2009-04/06/content_11138803.htm [accessed 01.07.15].
8. OECD How does China compare? 2014, Paris.
9. WHO WHO Global Health Expenditure Database 2014, http://apps.who.int/nha/database/ViewData/Indicators/en [accessed 02.05.15].
10. McKinsey India Pharma 2020 2014, Mumbai.
11. Deloitte 2015 life sciences outlook Brazil 2015, Sao Paulo.
12. BMI Research Russia Pharmaceuticals & Healthcare Report 2015, London.
13. Center for Health Statistics and Information China health statistical handbook 2013, Beijing.
14. Tordoff J.M., Norris P.T., Reith D.M. Price management and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals. Value Health 2008, 11:1214-1226. 10.1111/j. 1524-4733.2008.00353.x.
15. Mossialos E., Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. International Journal of Health Planning and Management 2005, 20:291-306. 10.1002/hpm.816.
16. Lopez Bastida J., Mossialos E. Pharmaceutical expenditure in Spain: cost and control. International Journal of Health Services 2000, 30:597-616. 10.2190/YL3J-QK9B-0NMQ-KMVK.
17. IMS Health IMS market prognosis: China 2014, London.
18. NDRC The current status, existing problems and reform recommendations of China's pharmaceutical production and distribution system 2014, NDRC.
19. State Council State Council Organisation chart 2015, http://english.gov.cn/state_council/2014/09/03/content_281474985533579.htm [accessed 15.04.15].
20. Wang K., Lin G. Pharmaceutical IP and competition law in China: overview 2014, Shanghai.
21. McTiernan R. Au revoir to Anhui? China's shape-shifting tenders 2014, Shanghai.
22. State Council Development Research Center Development Research Center joint seminars 2015, Beijing.
23. NHFPC Prohibition on 9 unethical conducts to strengthen morals in the healthcare industry 2013, Beijing.
24. State Council Development Research Center Development Research Center joint seminars 2014, Beijing.
25. Chen Z. Early results of China's historic health reforms: the view from minister Chen Zhu. Interview by Tsung-Mei Cheng. Health Affairs 2012, 31:2536-2544. 10.1377/hlthaff.2012.1017.
26. Barber S.L., Yao L. Health insurance systems in China: a briefing note 2010, Geneva.
27. Niu L. Healthcare in China: a Kieger report on the Chinese healthcare market 2015, Zurich.
28. Hsiao W., Li M., Zhang S. Universal health coverage: the case of China 2014, Geneva.
29. Meng Q., Yang H., Chen W., Sun Q., Liu X. People's Republic of China health system review 2015, Geneva.
30. Gong P., Liang S., Carlton E.J., Jiang Q., Wu J., Wang L., et al. Urbanisation and health in China. Lancet 2012, 379:843-852. 10.1016/S0140-6736(11)61878-3.
31. Jiang M., Yang S., Yan K., Liu J., Zhao J., Fang Y. Measuring access to medicines: a survey of prices, availability and affordability in Shaanxi province of China. PLoS ONE 2013, 8. 10.1371/journal.pone.0070836.
32. Jiang M., Zhou Z., Wu L., Shen Q., Lv B., Wang X., et al. Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future. International Journal of Clinical Pharmacy 2014, 37:12-17. 10.1007/s11096-014-0037-4.
33. IBISWorld Industry Report Pharmaceutical manufacturing in China 2015, Beijing.
34. Tse E., Pan P., Sun S., Ma K. Changing landscape of China's pharmaceutical distribution industry Shanghai 2012, Beijing.
35. IBISWorld Industry Report Pharmacies & drugstores in China 2015, Beijing.
36. Mossialos E., Mrazek M., Walley T. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality 2004, Open University Press, Berkshire.
37. CFDA Center for Drug Evaluation 2014 annual report on drug review 2015, Beijing.
38. World Bank Financing, pricing, and utilization of pharmaceuticals in China: the road to reform 2010, Washington, DC.
39. Qi M. The analysis of Chinese drug safety supervision and management. Chinese Law and Government 2012, 45:3-8. 10.2753/CLG0009-4609450200.
40. Hu S., Zhang Y., He J., Du L., Xu M., Xie C., et al. A case study of pharmaceutical pricing in China: setting the price for off-patent originators. Applied Health Economics and Health Policy 2015, 13:13-20.
41. Vincent D.W. Quality and compliance in the Asian pharmaceutical industry 2014, Inst Valid Technol, [accessed 08.08.15]. http://www.ivtnetwork.com/article/quality-and-compliance-asian-pharmaceutical-industry.
42. Sun Y. The situation on GMP and regulatory compliance for APIs manufactured in China 2007, Beijing CHNMED Pharmaceutical Consulting, Beijing.
43. US-China Economic and Security Review Commission 2014 report to congress of the US-China Economic and Security Review Commission 2014, Washington, DC.
44. CFDA On soliciting public opinions regarding policies to expedite the reduction of drug registration application backlog: Document #140 2015, Beijing.
45. Boston Consulting Group New rules for winning in China's pharmaceutical market 2014, Hong Kong.
46. Wang X., Fang Y., Yang S., Jiang M., Yan K., Wu L., et al. Access to paediatric essential medicines: a survey of prices, availability, affordability and price components in Shaanxi province, China. PLOS ONE 2014, 9:e90365. 10.1371/journal.pone.0090365.
47. Wu B., Zhang Q., Qiao X. Effects of pharmaceutical price regulation: China's evidence between 1997 and 2008. Journal of the Asia Pacific Economy 2014, 20. 10.1080/13547860.2014.964968.
48. Han S., Liang H., Su W., Xue Y., Shi L. Can price controls reduce pharmaceutical expenses? A case study of antibacterial expenditures in 12 Chinese hospitals from 1996 to 2005. International Journal of Health Services 2013, 43:91-103. 10.2190/HS.43.1.g.
49. NDRC Promoting reform of the current drug pricing scheme 2014, Beijing.
50. Yang C., Lei L. Drug procurement bidding 2010, Washington, DC.
51. Hu S. Essential medicine policy in China: pros and cons. Journal of Medical Economics 2013, 16:289-294.
52. Barber S.L., Huang B., Santoso B., Laing R., Paris V., Wu C. The reform of the essential medicines system in China: a comprehensive approach to universal coverage. Journal of Global Health 2013, 3:010303.
53. State Council Implementing and improving centralized bidding and procurement of drugs (Document #7) 2015, Beijing.
54. NHFPC Implementing and improving centralized bidding and procurement of drugs (Document #70) 2015, Beijing.
55. Pharmnet Perspective on new tendering platforms in three provinces: will drug prices collapses? 2015, Pharmnet, http://news.pharmnet.com.cn/news/2015/07/09/423811.html [accessed 13.01.15].
56. Sai B. NHFPC: transparent tendering and secondary negotiations 2015, http://info.pharmacy.hc360.com/2015/10/220858577827.shtml [accessed 30.01.16].
57. PharmNet Three provinces to centralize tendering and procurement 2015, http://news.pharmnet.com.cn/news/2015/07/09/423811.html [accessed 30.01.16].
58. NDRC Improving the monitoring of drug prices - discussion paper 2015, Beijing.
59. McTiernan R. Pricing play: NDRC reveals liberalization hand 2015, Shanghai.
60. Oortwijn W., Mathijssen J., Banta D. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Health Policy (New York) 2010, 95:174-184.
61. Zhao K. HTA in development assistance to health: potential and challenge in China 2014, China National Health Development Research Centre, Beijing.
62. Kennedy-Martin T., Mitchell B.D., Boye K.S., Chen W., Curtis B.H., Flynn J.A., et al. The health technology assessment environment in Mainland China, Japan, South Korea, and Taiwan-implications for the evaluation of diabetes mellitus therapies. Value in Health Regional Issues 2014, 3:108-116.
63. Ellis S. China's "zero markup" hospital reforms mixed bag for patented drugs 2015, BioWorld, http://www.bioworld.com/content/chinas-zero-markup-hospital-reforms-mixed-bag-patented-drugs-2 [accessed 13.03.16].
64. State Council State Council healthcare reform 2015 work plan 2015, Beijing.
65. Zhang X., Wu Q., Liu G., Li Y., Gao L., Guo B., et al. The effect of the National Essential Medicines Policy on health expenditures and service delivery in Chinese township health centres: evidence from a longitudinal study. BMJ Open 2014, 4:e006471.
66. Song Y., Bian Y., Petzold M., Li L., Yin A. The impact of China's national essential medicine system on improving rational drug use in primary health care facilities: an empirical study in four provinces. BMC Health Services Research 2014, 14:1-7.
67. Chen M., Wang L., Chen W., Zhang L., Jiang H., Mao W. Does economic incentive matter for rational use of medicine? China's experience from the essential medicines program. Pharmacoeconomics 2014, 32:245-255. 10.1007/s40273-013-0068-z.
68. Xiang X., Yang C., Wang D., Ye J., Zhang X. Effects of China's national essential medicines policy on the use of injection in primary health facilities. Journal of Huazhong University of Science and Technology - Medical Sciences 2012, 32:626-629. 10.1007/s11596-012-1008-4.
69. Yi H., Miller G., Zhang L., Li S., Rozelle S. Intended and unintended consequences of China's Zero Markup Drug Policy. Health Affairs 2015, 34:1391-1398.
70. Zhou Z., Su Y., Campbell B., Zhou Z., Gao J., Yu Q., et al. The financial impact of the Zero-Markup Policy for Essential Drugs on patients in county hospitals in western rural China. PLOS ONE 2015, 10:e0121630.
71. Zhou Z., Su Y., Campbell B., Zhou Z., Gao J., Yu Q., et al. The impact of China's Zero-Markup Drug Policy on county hospital revenue and government subsidy levels. Journal of Asian Public Policy 2015, 8:102-116.
72. Wang Y. NHFPC, MOF, State Council Joint Evaluation of Public Hospital Reform 2015, http://www.cbda.cn/html/MDnews/20150729/64734.html [accessed 13.08.15].
73. IMS Health Exploring impacts of the revised EDL and associated policies 2013, Shanghai.
74. Tian X., Song Y., Zhang X. National Essential Medicines List and policy practice: a case study of China's health care reform. BMC Health Services Research 2012, 12:401.
75. Li Y., Ying C., Sufang G., Brant P., Bin L., Hipgrave D. Evaluation, in three provinces, of the introduction and impact of China's National Essential Medicines Scheme. Bulletin of the World Health Organization 2013, 91:184-194.
76. Yoongthong W., Hu S., Whitty J.A., Wibulpolprasert S., Sukantho K., Thienthawee W., et al. National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities. Value Health 2012, 15:126-131. 10.1016/j.jval.2011.11.003.
77. IMS Health China IMS pharmaceutical pricing & reimbursement concise guide 2013, London.
78. Ngorsuraches S., Meng W., Kim B.Y., Kulsomboon V. Drug reimbursement decision-making in Thailand, China, and South Korea. Value Health 2012, 15:S120-S125.
79. IMS Health research report on establishing an optimal reimbursement system in China 2014, Beijing.
80. Xue K. Le Keqiang announce major diseases scheme: who benefits? Who will pay? How will it be implemented? 2015, http://info.pharmacy.hc360.com/2015/07/270910566332.shtml [accessed 13.08.15].
81. NDRC Academy of Macroeconomic Research NDRC: approaching reimbursement caps 2015, Beijing.
82. Reynolds L., McKee M. Factors influencing antibiotic prescribing in China: an exploratory analysis. Health Policy (New York) 2009, 90:32-36.
83. McTiernan R. Pipe dreams CDE offers dose of realism on DAL, DRR reforms 2015, Shanghai.